Gabapentin reduces haloperidol-induced vacuous chewing movements in mice

Area of Science:

• Neuroscience
• Pharmacology
• Movement Disorders

Background:

• Tardive dyskinesia (TD) is a prevalent side effect of long-term antipsychotic use.
• Dopamine supersensitivity and GABA deficiency are implicated in TD pathogenesis.
• Haloperidol-induced vacuous chewing movements (VCMs) serve as an animal model for TD.

Purpose of the Study:

• To investigate the efficacy of gabapentin, a GABA-mimetic drug, in preventing haloperidol-induced VCMs.
• To assess the impact of gabapentin on locomotor activity in an animal model of TD.

Main Methods:

• Male mice were administered haloperidol, gabapentin, or vehicle daily for 28 days.
• Vacuous chewing movements (VCMs) were quantified before and after treatment.
• Locomotor activity was assessed using an open-field test.

Main Results:

• Gabapentin administration significantly prevented the development of haloperidol-induced VCMs.
• Haloperidol-induced reduction in locomotor activity was ameliorated by gabapentin co-treatment.
• No significant changes were observed in striatal tyrosine hydroxylase (TH) or glutamic acid decarboxylase (GAD) immunoreactivity or monoamine levels.

Conclusions:

• Gabapentin demonstrates potential as a therapeutic agent for attenuating antipsychotic-induced movement abnormalities.
• The protective effects of gabapentin occur without altering key dopaminergic or GABAergic markers in the striatum.